Episode Details

Indias generic drug makers are capitalizing on the expiration of Novo Nordisks semaglutide patent, offering low-cost versions of the weight-loss and diabetes drug. With Indias vast overweight population and rising obesity rates, these generics could significantly impact access and costs, potentially setting a precedent for other countries like China, Brazil, and Turkey.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/f56d1035f3302055